基于患者报告老年综合评估的衰弱指数可预测胃肠道肿瘤老年患者的不良结局
研究在589例≥60岁胃肠道肿瘤患者中,用44项患者报告老年综合评估构建衰弱指数(CARE-FI),分为健壮、衰弱前期和衰弱。衰弱(vs健壮)与更差总生存(HR 1.83,95%CI 1.34-2.49,p<0.001)、功能下降(OR 3.01,95%CI 1.33-6.81,p=0.008)及≥3级非血液学毒性(OR 3.65,95%CI 1.54-8.69,p=0.003)相关,但与血液学毒性无关。
要点
- 患者报告GA构建的CARE-FI可识别胃肠道肿瘤老年患者不良结局风险。
- 衰弱与更差总生存、功能下降及≥3级非血液学毒性独立相关。
- 衰弱与血液学毒性无显著关联。
核心结论
- 基于患者报告老年综合评估的衰弱指数是胃肠道肿瘤老年患者生存、功能下降和治疗相关毒性的稳健预测因子。
研究设计与样本
- 单中心前瞻性注册研究,纳入≥60岁胃肠道肿瘤老年患者589例,中位年龄69岁,55%男性,73%白人。
- 采用缺陷累积法构建44项衰弱指数(CARE-FI),将患者分为健壮、衰弱前期和衰弱。
- 主要结局为总生存,次要结局为治疗后3个月功能下降和治疗后6个月≥3级治疗相关毒性。
- 使用多变量Cox和logistic回归模型分析衰弱对主要和次要结局的影响。
主要发现
- 168例(29%)为衰弱前期,230例(39%)为衰弱。
- 调整年龄、性别、种族/民族、癌症类型、癌症分期和治疗线数后,衰弱(vs健壮)与更差总生存相关(HR 1.83,95%CI 1.34-2.49,p<0.001)。
- 衰弱与功能下降风险增加相关(OR 3.01,95%CI 1.33-6.81,p=0.008)。
- 衰弱与≥3级非血液学毒性风险增加相关(OR 3.65,95%CI 1.54-8.69,p=0.003),但与血液学毒性无关(OR 1.01,95%CI 0.46-2.22,p=0.97)。
临床怎么用
- 在老年胃肠道肿瘤患者初次评估时,可采用患者报告GA构建的CARE-FI进行衰弱分层,识别不良结局高风险患者。
- 对衰弱患者应加强生存预期、功能下降和非血液学毒性的监测与干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults with cancer are at increased risk of treatment-related toxicities and excess mortality. We evaluated whether a patient-reported geriatric assessment (GA) based frailty index can identify those at risk of adverse outcomes. METHODS: Older adults (≥60 years) enrolled in a single-institutional prospective registry underwent patient-reported GA at initial evaluation in our medical oncology clinic. Using deficit accumulation method, we constructed a 44-item frailty index (CARE-FI), categorizing patients as robust, pre-frail, and frail. The primary outcome was overall survival (OS). Secondary outcomes included (a) functional decline at 3 months post-therapy (b) incident grade ≥3 treatment-related toxicities at six-month post-treatment. We used multivariate Cox and logistic regression models respectively to study the impact of frailty on primary and secondary outcomes. RESULTS: We identified 589 older adults with a median age of 69 years; 55% males and 73% Whites. Overall, 168 (29%) were pre-frail and 230 (39%) frail. Being frail (vs. robust) was associated with worse OS (Hazards Ratio, HR 1.83, 95% Confidence Interval, CI 1.34-2.49, p < 0.001) after adjusting for age, sex, race/ethnicity, cancer type, cancer stage, and line of therapy. Similarly, frailty was associated with increased risk of functional decline (OR 3.01; 95% CI 1.33-6.81; p = 0.008) and grade ≥3 non-hematologic toxicities (OR 3.65; 95% CI 1.54-8.69; p = 0.003) but not hematologic toxicities (OR 1.01; 95% CI 0.46-2.22; p = 0.97). CONCLUSIONS: Our frailty index using a patient-reported GA is a robust predictor of survival, functional decline, and treatment related toxicity among older adults with GI malignancies.
引用
- Giri S, Al-Obaidi M, Harmon C, et al. Patient-reported geriatric assessment-based frailty index among older adults with gastrointestinal malignancies. J Am Geriatr Soc. 2022. PMID: 36208421. doi:10.1111/jgs.18054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。